<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2018-3-341-352</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1539</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ЗНАЧЕНИЕ СООТНОШЕНИЯ КОНЦЕНТРАЦИЙ ЛЕПТИНА И ГРЕЛИНА КАК БИОМАРКЕРА ПРИ ИНДУЦИРОВАННОЙ ДИЕТОЙ ГИПЕРЛИПИДЕМИИ У САМОК МЫШЕЙ C57Black/6J</article-title><trans-title-group xml:lang="en"><trans-title>IMPORTANCE OF THE LEPTIN/GRELIN RATIO AS A BIOMARKER IN DIETARY INDUCED HYPERLIPIDEMIA IN FEMALE C57Black/6 MICE</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ригер</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Riger</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ригер Николай Александрович – Доктор медицинских наук, старший научный сотрудник лаборатории иммунологии.</p><p>109240, Москва, Устьинский проезд, 2/14, тел.: 8 (495) 698-53-45</p></bio><bio xml:lang="en"><p>Riger Nikolay A. - PhD, MD (Medicine), Senior Research Associate, Laboratory of Immunology.</p><p>109240, Moscow, Ustinski proezd, 2/14, phone: 7 (495) 698-53-45</p></bio><email xlink:type="simple">riger@ion.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Евстратова</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Evstratova</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Младший научный сотрудник лаборатории иммунологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>Junior Research Associate, Laboratory of Immunology.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Апрятин</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Apryatin</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат биологических наук, старший научный сотрудник лаборатории метаболомного и протеомного анализа.</p><p>Москва</p></bio><bio xml:lang="en"><p>PhD (Biology), Senior Research Associate, Laboratory of Proteomic and Genomic Analysis.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гмошинский</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gmoshinskiy</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор биологических наук, ведущий научный сотрудник лаборатории пищевой токсикологии и оценки безопасности нанотехнологий.</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Leading Research Associate, Laboratory of Food Toxicology and Nanotechnology Safety Evaluation.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ханферьян</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khanferyan</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующий лабораторией иммунологии.</p><p>Москва</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Laboratory of Immunology.</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУН Федеральный исследовательский центр питания и биотехнологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Center of Nutrition and Biotechnology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>11</day><month>06</month><year>2018</year></pub-date><volume>20</volume><issue>3</issue><fpage>341</fpage><lpage>352</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ригер Н.А., Евстратова В.С., Апрятин С.А., Гмошинский И.В., Ханферьян Р.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Ригер Н.А., Евстратова В.С., Апрятин С.А., Гмошинский И.В., Ханферьян Р.А.</copyright-holder><copyright-holder xml:lang="en">Riger N.A., Evstratova V.S., Apryatin S.A., Gmoshinskiy I.V., Khanferyan R.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/1539">https://www.mimmun.ru/mimmun/article/view/1539</self-uri><abstract><p>Висцеральное ожирение, дислипидемия и инсулинорезистентность рассматриваются как основные причины обменных нарушений при метаболическом синдроме. Лептин и грелин являются важнейшими факторами, участвующими в регуляции метаболических процессов. Целью настоящего исследования была оценка значимости соотношения концентраций лептина и грелина (L/Gh), а также цитокинового профиля в качестве биомаркеров метаболических и иммунных нарушений на in vivo модели индуцированной диетой дислипидемии у мышей.</p><p>Исследования проводили на 48 мышах-самках линии C57Black/6, которые были разделены на 6 групп по 8 животных. Группа 1 (контроль) получала рацион AIN93; 2 – избыток жиров (30% сухой массы); 3 – добавку 20% фруктозы с водой к основному рациону; 4 – избыток жиров и фруктозы; 5 – избыток холестерина (0,5% сухой массы); 6 – избыток холестерина и фруктозы. Продолжительность эксперимента составила 63 суток. У всех животных определяли относительную массу внутренних органов. Уровни цитокинов, лептина и грелина в плазме определяли на анализаторе Luminex 200 с использованием наборов Bio-Plex.</p><p>Не было выявлено значимых различий концентраций лептина и грелина в плазме животных между контролем и большинством опытных групп, за исключением 6-й группы (комбинированный рацион с избытком фруктозы и холестерина), в которой уровень лептина был достоверно снижен по сравнению с контролем (группа 6: 2,12 пг/мл, min 1,57 – max 3,83 vs группа 1: 3,92 пг/мл, min 2,45 – max 27,88; p &lt; 0,05). Изменения содержания грелина в плазме, в зависимости от рационов, имели в целом обратную тенденцию по сравнению с лептином. Величина L/Gh при избытке жировой (группа 2) и холестериновой (группа 5) составляющей имела статистически недостоверные тенденции к возрастанию. Добавление фруктозы к рациону с избытком жира или холестерина достоверно (p &lt; 0,05) снижало L/Gh. У животных 6-й группы (фруктоза + холестерин) при минимальном L/Gh выявлена наименьшая общая масса жировых отложений. Связь между L/Gh и массой жира была подтверждена наличием линейной регрессионной зависимости между рассматриваемыми показателями. Также были обнаружены корреляционные связи между значениями L/Gh и показателями массы тела животных (r = 0,424; α = 0,004), относительной массы жировой ткани (r = 0,663; α = 0,000), печени (r = -0,315; α = 0,035) и селезенки (r = -0,585; α = 0,000), статистически значимые корреляции между L/Gh, массой органов и тканей и концентрациями IL-12(p40), IL-2, IL-9, IL- 13, G-CSF и RANTES. Наряду с этим, установлены достоверные различия между контрольной и опытными группами по концентрациям в плазме G-CSF, IL-12(p40), IL-2, IL-3 и IL-9. Концентрация IL-12(p40) в плазме группы 2 была самой низкой по сравнению с контролем, а в 6-й группе на фоне самых низких показателей L/Gh и общего количества жира уровень IL-12(p40) был самым высоким.</p><p>Таким образом, была выявлена достоверная зависимость между L/Gh с изменениями массы органов и тканей, а также с уровнями цитокинов, участвующих в регуляции воспаления. Наиболее значимая взаимосвязь обнаружена между относительной массой жировых отложений, соотношением L/Gh и концентрацией IL-12(p40). При этом отмечается не только корреляционная зависимость, но и достоверные изменения L/Gh и содержания IL-12(p40) между опытными группами на in vivo модели алиментарной дислипидемии у мышей.</p></abstract><trans-abstract xml:lang="en"><p>Visceral obesity, dyslipidemia and insulin resistance are considered the main causes of metabolic disorders in metabolic syndrome. Leptin and ghrelin are the most important factors involved in regulation of the metabolic processes. The purpose of this study was to evaluate the significance of leptin-to-ghrelin ratio (L/Gh) and cytokine profiles as biomarkers of metabolic and immune disorders in an in vivo model of a dietary induced dyslipidemia in mice.</p><p>The studies were carried out on 48 female C57Black/6 mice, which were divided into 6 groups of 8 animals. Group 1 (control) received the AIN93 diet; group 2, excess fat administration (30% dry weight); the mice from group 3 were supplied with 20% fructose in drinking water added to the main diet; group 4 got fats and fructose excess, group 5, cholesterol excess (0.5% dry weight); group 6 was fed with cholesterol and fructose in excess. Duration of the experiment was 63 days. In all animals, the relative mass of internal organs was determined. The levels of cytokines, leptin and ghrelin in plasma were determined by means of Luminex 200 analyzer using Bio-Plex kits.</p><p>There were no significant differences for plasma leptin and ghrelin concentrations between the control and most of experimental groups, except of the 6th group (combined diet with excess fructose and cholesterol) which a significantly lower leptin levels as compared to the controls (group 6: 2.12 pg/ml, min 1.57 – max 3.83 vs group 1: 3.92 pg/ml, min 2.45 – max 27.88, p &lt; 0.05). The changes in plasma ghrelin contents, depending on the diet, showed a generally opposite trend when compared to leptin levels.</p><p>The value of L/Gh ratio in mice fed with excess fat (group 2) and cholesterol (group 5) showed a statistically unsignificant trend for increase. Fructose added to a diet with fat or cholesterol excess caused a significant decrease in L/Gh ratio (p &lt; 0.05). In animals of the 6th group (fructose + cholesterol) with minimal L/Gh values, the lowest total body fat deposition was found. The relationship between the L/Gh and the fat mass was confirmed by the linear regression relationship between the indicators considered. We have also found a correlation between L/Gh and animal fat weight (r = 0.424, α = 0.004), relative mass of adipose tissue (r = 0.663, α = 0.000), liver (r = -0.315, α = 0.035) and spleen (r = -0.585; α = 0.000), statistically significant correlations between L/Gh, organ and tissue weight and concentrations of IL-12(p40), IL-2, IL-9, IL-13, G-CSF and RANTES. In addition, significant differences were found between the control and test groups for plasma concentrations of G-CSF, IL-12(p40), IL-2, IL-3 and IL-9. The IL-12(p40) concentration in plasma from the group 2 mice was the lowest against controls. Meanwhile, the 6th group exhibited highest IL-12(p40) levels against the lowest L/Gh ratios and total fat levels.</p><p>Thus, a significant relationship was found between L/Gh ratio and changing mass of organs and tissues, as well as with the levels of cytokines involved into the regulation of inflammation. The most significant relationship was found between the relative mass of body fat, L/Gh ratio and the IL-12(p40) concentration. L/ Gh ratio and IL-12p(40) showed both content Not only a correlation dependence, but also significant changes were noted between the experimental groups in the in vivo model of alimentary dyslipidemia in mice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>лептин</kwd><kwd>грелин</kwd><kwd>гиперлипидемия</kwd><kwd>цитокины</kwd><kwd>биомаркеры</kwd><kwd>корреляция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>leptin</kwd><kwd>ghrelin</kwd><kwd>hyperlipidemia</kwd><kwd>cytokines</kwd><kwd>biomarkers</kwd><kwd>correlation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Апрятин С.А., Мжельская К.В., Трусов Н.В., Балакина А.С., Кулакова С.Н., Сото Х.С., Макаренко М.А., Ригер Н.А., Тутельян В.А. Сравнительная характеристика in vivo моделей гиперлипидемии у крыс линии Вистар и мышей линии C57Bl/6 // Вопросы питания, 2016. Т. 85, № 6. С. 14-23.</mixed-citation><mixed-citation xml:lang="en">Apryatin S.A., Mzhelskaya K.V., Trusov N.V., Balakina A.S., Kulakova S.N., Soto S.Kh., Makarenko M.A., Riger N.A., Tutelyan V.A. Comparative characteristics of in vivo models of hyperlipidemia in Wistar rats and C57Bl/6 mice. Voprosy pitaniya = Problems of Nutrition, 2016, Vol. 85, no. 6, pp. 14-23. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Aroor A.R., McKarns S., Demarco V.G., Jia G., Sowers J.R. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism, 2013, Vol. 62, no. 11, pp. 1543-1552.</mixed-citation><mixed-citation xml:lang="en">Aroor A.R., McKarns S., Demarco V.G., Jia G., Sowers J.R. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism, 2013, Vol. 62, no. 11, pp. 1543-1552.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Baumann H., Morella K.K., White D.W., Dembski M., Bailon P.S., Kim H., Lai C.F., Tartaglia L.A. The fulllength leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl. Acad. Sci. USA, 1996, Vol. 93, no. 16, pp. 8374-8378.</mixed-citation><mixed-citation xml:lang="en">Baumann H., Morella K.K., White D.W., Dembski M., Bailon P.S., Kim H., Lai C.F., Tartaglia L.A. The fulllength leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc. Natl. Acad. Sci. USA, 1996, Vol. 93, no. 16, pp. 8374-8378.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Choi K.M., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., Choi D.S., Baik S.H. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Research and Clinical Practice, 2007, Vol. 75, no. 2, pp. 235-240.</mixed-citation><mixed-citation xml:lang="en">Choi K.M., Ryu O.H., Lee K.W., Kim H.Y., Seo J.A., Kim S.G., Choi D.S., Baik S.H. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Research and Clinical Practice, 2007, Vol. 75, no. 2, pp. 235-240.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cicero A.F., Magni P., More M., Ruscica M., Borghi C., Strollo F. Brisighella heart study staff. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obesity Facts, 2012, Vol. 5, no. 3, pp. 319-326.</mixed-citation><mixed-citation xml:lang="en">Cicero A.F., Magni P., More M., Ruscica M., Borghi C., Strollo F. Brisighella heart study staff. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obesity Facts, 2012, Vol. 5, no. 3, pp. 319-326.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Claycombe K., King L.E., Fraker P.J. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proc. Natl. Acad. Sci. USA, 2008, Vol. 105, no. 6, pp. 2017-2021.</mixed-citation><mixed-citation xml:lang="en">Claycombe K., King L.E., Fraker P.J. A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proc. Natl. Acad. Sci. USA, 2008, Vol. 105, no. 6, pp. 2017-2021.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cong W.N., Golden E., Pantaleo N., White C.M., Maudsley S., Martin B. Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS and Neurological Disorders Drug Targets, 2010, Vol. 9, no. 5, pp. 557-563.</mixed-citation><mixed-citation xml:lang="en">Cong W.N., Golden E., Pantaleo N., White C.M., Maudsley S., Martin B. Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS and Neurological Disorders Drug Targets, 2010, Vol. 9, no. 5, pp. 557-563.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cui H., López M., Rahmouni K. The cellular and molecular bases of leptin and ghrelin resistance in obesity. Nat. Rev. Endocrinol., 2017, Vol. 13, no. 6, pp. 338-351.</mixed-citation><mixed-citation xml:lang="en">Cui H., López M., Rahmouni K. The cellular and molecular bases of leptin and ghrelin resistance in obesity. Nat. Rev. Endocrinol., 2017, Vol. 13, no. 6, pp. 338-351.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Deng Y., Scherer P.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Academy of Sciences, 2011, Vol. 1226, no. 1, pp. 50-69.</mixed-citation><mixed-citation xml:lang="en">Deng Y., Scherer P.E. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Academy of Sciences, 2011, Vol. 1226, no. 1, pp. 50-69.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dong M., Ren J. What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Current Pharmaceutical Design, 2014, Vol. 20, no. 4, pp. 652-658.</mixed-citation><mixed-citation xml:lang="en">Dong M., Ren J. What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Current Pharmaceutical Design, 2014, Vol. 20, no. 4, pp. 652-658.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Falahi E., Khalkhali Rad A.H., Roosta S. What is the best biomarker for metabolic syndrome diagnosis? Diabetes Metab. Syndr., 2015, Vol. 9, no. 4, pp. 366-372.</mixed-citation><mixed-citation xml:lang="en">Falahi E., Khalkhali Rad A.H., Roosta S. What is the best biomarker for metabolic syndrome diagnosis? Diabetes Metab. Syndr., 2015, Vol. 9, no. 4, pp. 366-372.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol., 2000, Vol. 68, no. 4, pp. 437-446.</mixed-citation><mixed-citation xml:lang="en">Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol., 2000, Vol. 68, no. 4, pp. 437-446.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Finucane F.M., Luan J., Wareham N.J., Sharp S.J., O’Rahilly S., Balkau B., Flyvbjerg A., Walker M., Højlund K., Nolan J., Savage DB. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia, 2009, Vol. 52, no. 11, pp. 2345-2349.</mixed-citation><mixed-citation xml:lang="en">Finucane F.M., Luan J., Wareham N.J., Sharp S.J., O’Rahilly S., Balkau B., Flyvbjerg A., Walker M., Højlund K., Nolan J., Savage DB. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia, 2009, Vol. 52, no. 11, pp. 2345-2349.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guide for the care and use of laboratory animals. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; Institute for Laboratory Animal Research (ILAR); Division on Earth and Life Studies (DELS); National Research Council of the national academies. 8th Ed. Washington: The National Academies Press, 2011, 248 p.</mixed-citation><mixed-citation xml:lang="en">Guide for the care and use of laboratory animals. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; Institute for Laboratory Animal Research (ILAR); Division on Earth and Life Studies (DELS); National Research Council of the national academies. 8th Ed. Washington: The National Academies Press, 2011, 248 p.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Howard J.K., Lord G.M., Matarese G., Vendetti S., Ghatei M.A., Ritter M.A., Lechler R.I., Bloom S.R. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest., 1999, Vol. 104, no. 8, pp. 1051-1059.</mixed-citation><mixed-citation xml:lang="en">Howard J.K., Lord G.M., Matarese G., Vendetti S., Ghatei M.A., Ritter M.A., Lechler R.I., Bloom S.R. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J. Clin. Invest., 1999, Vol. 104, no. 8, pp. 1051-1059.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kashani A., Salehi B., Anghesom D., Kawayeh A.M., Rouse G.A., Runyon B.A. Spleen size in cirrhosis of different etiologies. J. Ultrasound. Med., 2015, Vol. 34, no. 2, pp. 233-238.</mixed-citation><mixed-citation xml:lang="en">Kashani A., Salehi B., Anghesom D., Kawayeh A.M., Rouse G.A., Runyon B.A. Spleen size in cirrhosis of different etiologies. J. Ultrasound. Med., 2015, Vol. 34, no. 2, pp. 233-238.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Katare R., Rawal S., Munasinghe P.E., Tsuchimochi H., Inagaki T., Fujii Y., Dixit P., Umetani K., Kangawa K., Shirai M., Schwenke D.O. Ghrelin promotes functional angiogenesis in a mouse model of critical limb ischemia through activation of proangiogenic microRNAs. Endocrinology, 2016, Vol. 157, no. 2, pp. 432-445.</mixed-citation><mixed-citation xml:lang="en">Katare R., Rawal S., Munasinghe P.E., Tsuchimochi H., Inagaki T., Fujii Y., Dixit P., Umetani K., Kangawa K., Shirai M., Schwenke D.O. Ghrelin promotes functional angiogenesis in a mouse model of critical limb ischemia through activation of proangiogenic microRNAs. Endocrinology, 2016, Vol. 157, no. 2, pp. 432-445.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly A.S., Jacobs D.R. Jr., Sinaiko A.R., Moran A., Steffen L.M., Steinberger J. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatric. Diabetes, 2010, Vol. 11, no. 8, pp. 552-555.</mixed-citation><mixed-citation xml:lang="en">Kelly A.S., Jacobs D.R. Jr., Sinaiko A.R., Moran A., Steffen L.M., Steinberger J. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatric. Diabetes, 2010, Vol. 11, no. 8, pp. 552-555.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Khazaei M., Tahergorabi Z. Systemic ghrelin administration alters serum biomarkers of angiogenesis in diet-induced obese mice. Int. J. Pept., 2013, ID 249565, 5 p.</mixed-citation><mixed-citation xml:lang="en">Khazaei M., Tahergorabi Z. Systemic ghrelin administration alters serum biomarkers of angiogenesis in diet-induced obese mice. Int. J. Pept., 2013, ID 249565, 5 p.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kohno D., Nakata M., Maekawa F., Fujiwara K., Maejima Y., Kuramochi M., Shimazaki T., Okano H., Onaka T., Yada T. Leptin suppresses ghrelin-induced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol 3-kinase- and phosphodiesterase 3-mediated pathway. Endocrinology, 2007, Vol. 148, no. 5, pp. 2251-2263.</mixed-citation><mixed-citation xml:lang="en">Kohno D., Nakata M., Maekawa F., Fujiwara K., Maejima Y., Kuramochi M., Shimazaki T., Okano H., Onaka T., Yada T. Leptin suppresses ghrelin-induced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol 3-kinase- and phosphodiesterase 3-mediated pathway. Endocrinology, 2007, Vol. 148, no. 5, pp. 2251-2263.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kotani K., Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. Korean J. Lab. Med., 2011, Vol. 31, no. 3, pp. 162-166.</mixed-citation><mixed-citation xml:lang="en">Kotani K., Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. Korean J. Lab. Med., 2011, Vol. 31, no. 3, pp. 162-166.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kraja A.T., Province M.A., Arnett D., Wagenknecht L., Tang W., Hopkins P.N. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutrition and metabolism, 2007, Vol. 4, no. 1, pp. 28-40.</mixed-citation><mixed-citation xml:lang="en">Kraja A.T., Province M.A., Arnett D., Wagenknecht L., Tang W., Hopkins P.N. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutrition and metabolism, 2007, Vol. 4, no. 1, pp. 28-40.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lam Q.L., Lu L. Role of leptin in immunity. Cell. Mol. Immunol., 2007, Vol. 4, no. 1, pp. 1-13.</mixed-citation><mixed-citation xml:lang="en">Lam Q.L., Lu L. Role of leptin in immunity. Cell. Mol. Immunol., 2007, Vol. 4, no. 1, pp. 1-13.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lee B.C., Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesityinduced insulin resistance. Biochim. Biophys. Acta, 2014, Vol. 1842, no. 3, pp. 446-462.</mixed-citation><mixed-citation xml:lang="en">Lee B.C., Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesityinduced insulin resistance. Biochim. Biophys. Acta, 2014, Vol. 1842, no. 3, pp. 446-462.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Li L., Duan M., Chen W., Jiang A., Li X., Yang J., Li Z. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J. Transl. Med., 2017, Vol. 15, no. 1, pp. 111-120.</mixed-citation><mixed-citation xml:lang="en">Li L., Duan M., Chen W., Jiang A., Li X., Yang J., Li Z. The spleen in liver cirrhosis: revisiting an old enemy with novel targets. J. Transl. Med., 2017, Vol. 15, no. 1, pp. 111-120.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">López-Jaramillo P., Gómez-Arbeláez D., López-López J., López-López C., Martínez-Ortega J., GómezRodríguez A., Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm. Mol. Biol. Clin. Invest., 2014, Vol. 18, no. 1, pp. 37-45.</mixed-citation><mixed-citation xml:lang="en">López-Jaramillo P., Gómez-Arbeláez D., López-López J., López-López C., Martínez-Ortega J., GómezRodríguez A., Triana-Cubillos S. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm. Mol. Biol. Clin. Invest., 2014, Vol. 18, no. 1, pp. 37-45.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Martinelli N., Micaglio R., Consoli L., Guarini P., Grison E., Pizzolo F., Friso S., Trabetti E., Pignatti P.F., Corrocher R., Olivieri O., Girelli D. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp. Diabetes Res., 2012, Vol. 2012, ID 231502, 9 p.</mixed-citation><mixed-citation xml:lang="en">Martinelli N., Micaglio R., Consoli L., Guarini P., Grison E., Pizzolo F., Friso S., Trabetti E., Pignatti P.F., Corrocher R., Olivieri O., Girelli D. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Exp. Diabetes Res., 2012, Vol. 2012, ID 231502, 9 p.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Musialik K. The influence of chosen adipocytokines on blood pressure values in patients with metabolic syndrome. Kardiol Pol., 2012, Vol. 70, no. 12, pp. 1237-1242.</mixed-citation><mixed-citation xml:lang="en">Musialik K. The influence of chosen adipocytokines on blood pressure values in patients with metabolic syndrome. Kardiol Pol., 2012, Vol. 70, no. 12, pp. 1237-1242.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Myers M.G. Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res., 2004, Vol. 59, pp. 287-304.</mixed-citation><mixed-citation xml:lang="en">Myers M.G. Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res., 2004, Vol. 59, pp. 287-304.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol., 2011, Vol. 11, no. 2, pp. 85-97.</mixed-citation><mixed-citation xml:lang="en">Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol., 2011, Vol. 11, no. 2, pp. 85-97.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Perello M., Scott M.M., Sakata I., Lee C.E., Chuang J.C., Osborne-Lawrence S., Rovinsky S.A., Elmquist J.K., Zigman J.M. Functional implications of limited leptin receptor and ghrelin receptor coexpression in the brain. J. Comp. Neurol., 2012, Vol. 520, pp. 281-294.</mixed-citation><mixed-citation xml:lang="en">Perello M., Scott M.M., Sakata I., Lee C.E., Chuang J.C., Osborne-Lawrence S., Rovinsky S.A., Elmquist J.K., Zigman J.M. Functional implications of limited leptin receptor and ghrelin receptor coexpression in the brain. J. Comp. Neurol., 2012, Vol. 520, pp. 281-294.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Pérez-Pérez A., Vilariño-García T., Fernández-Riejos P., Martín-González J., Segura-Egea J.J., SánchezMargalet V. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev., 2017, Vol. 35, pp. 71-84.</mixed-citation><mixed-citation xml:lang="en">Pérez-Pérez A., Vilariño-García T., Fernández-Riejos P., Martín-González J., Segura-Egea J.J., SánchezMargalet V. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev., 2017, Vol. 35, pp. 71-84.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Perna V., Perez-Perez A., Fernandez-Riejos P., Polo-Padillo J., Batista N., Dominguez-Castellano A., Sanchez-Margalet V. Effective treatment of pulmonary tuberculosis restores plasma leptin levels. Eur. Cytokine Netw., 2013, Vol. 24, no. 4, pp. 157-161.</mixed-citation><mixed-citation xml:lang="en">Perna V., Perez-Perez A., Fernandez-Riejos P., Polo-Padillo J., Batista N., Dominguez-Castellano A., Sanchez-Margalet V. Effective treatment of pulmonary tuberculosis restores plasma leptin levels. Eur. Cytokine Netw., 2013, Vol. 24, no. 4, pp. 157-161.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Reeves P.C. AIN-93 purified diets for the study of trace elements metabolism in rodents. Trace elements in laboratory rodents. Ed. Watson R.R., CRC Press. Ink., 1997, pp. 3-34.</mixed-citation><mixed-citation xml:lang="en">Reeves P.C. AIN-93 purified diets for the study of trace elements metabolism in rodents. Trace elements in laboratory rodents. Ed. Watson R.R., CRC Press. Ink., 1997, pp. 3-34.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., Nagai M., Matsuzawa Y., Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ. J., 2004, Vol. 68, no. 11, pp. 975-981.</mixed-citation><mixed-citation xml:lang="en">Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., Nagai M., Matsuzawa Y., Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ. J., 2004, Vol. 68, no. 11, pp. 975-981.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Silva H.A., Carraro J.C., Bressan J., Hermsdorff H.H. Relation between uric acid and metabolic syndrome in subjects with cardiometabolic risk. Einstein, 2015, Vol. 13, no. 2, pp. 202-208.</mixed-citation><mixed-citation xml:lang="en">Silva H.A., Carraro J.C., Bressan J., Hermsdorff H.H. Relation between uric acid and metabolic syndrome in subjects with cardiometabolic risk. Einstein, 2015, Vol. 13, no. 2, pp. 202-208.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Srikanthan K., Feyh A., Visweshwar H., Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int. J. Med. Sci., 2016, Vol. 13, no. 1, pp. 25-38.</mixed-citation><mixed-citation xml:lang="en">Srikanthan K., Feyh A., Visweshwar H., Sodhi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int. J. Med. Sci., 2016, Vol. 13, no. 1, pp. 25-38.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tartaglia L.A. The leptin receptor. J. Biol. Chem., 1997, Vol. 272, no. 10, pp. 6093-6096.</mixed-citation><mixed-citation xml:lang="en">Tartaglia L.A. The leptin receptor. J. Biol. Chem., 1997, Vol. 272, no. 10, pp. 6093-6096.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Trottier M.D., Naaz A., Li Y., Fraker P.J. Enhancement of hematopoiesis and lymphopoiesis in diet-induced obese mice. Proc. Natl. Acad. Sci. USA, 2012, Vol. 109, no. 20, pp. 7622-7629.</mixed-citation><mixed-citation xml:lang="en">Trottier M.D., Naaz A., Li Y., Fraker P.J. Enhancement of hematopoiesis and lymphopoiesis in diet-induced obese mice. Proc. Natl. Acad. Sci. USA, 2012, Vol. 109, no. 20, pp. 7622-7629.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Varela L., Vazquez M.J., Cordido F., Nogueiras R., Vidal-Puig A., Dieguez C., López M. Ghrelin and lipid metabolism: key partners in energy balance. J. Mol. Endocrinol., 2011, Vol. 46, no 2, pp. 43-63.</mixed-citation><mixed-citation xml:lang="en">Varela L., Vazquez M.J., Cordido F., Nogueiras R., Vidal-Puig A., Dieguez C., López M. Ghrelin and lipid metabolism: key partners in energy balance. J. Mol. Endocrinol., 2011, Vol. 46, no 2, pp. 43-63.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Williams R.L., Wood L.G., Collins C.E., Morgan P.J., Callister R. Energy homeostasis and appetite regulating hormones as predictors of weight loss in men and women. Appetite, 2016, Vol. 101, pp. 1-7.</mixed-citation><mixed-citation xml:lang="en">Williams R.L., Wood L.G., Collins C.E., Morgan P.J., Callister R. Energy homeostasis and appetite regulating hormones as predictors of weight loss in men and women. Appetite, 2016, Vol. 101, pp. 1-7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
